文献速递呼吸衰竭与机械通气创伤与烧伤重症综合管理与镇静镇痛

早期无创通气与经鼻高流量氧疗预防钝性胸部创伤低氧血症患者气管插管:OptiTHO随机试验

Early non-invasive ventilation and high-flow nasal oxygen therapy for preventing endotracheal intubation in hypoxemic blunt chest trauma patients: the OptiTHO randomized trial.
PubMed 文献 · Crit Care · 2023-04-26
一句话结论在高危钝性胸部创伤、非严重低氧血症且无急性呼吸衰竭征象的患者中,与常规氧疗联合晚期无创通气相比,经鼻高流量氧疗联合早期无创通气未降低气管插管率。

OptiTHO为随机、开放标签、多中心试验,纳入ICU收治48小时内的高危钝性胸部创伤成人患者(胸部创伤严重度评分≥8、估计PaO2/FiO2<300、无急性呼吸衰竭征象)。比较经鼻高流量氧疗联合早期无创通气(至少48小时)与常规氧疗联合晚期无创通气(呼吸恶化或PaO2/FiO2≤200 mmHg时启用)。因无效提前终止,共随机141例。实验组气管插管率7%(5/71)vs 对照组8.6%(6/70),校正OR=0.72(95%CI 0.20-2.43),p=0.60;肺部感染、迟发性血胸、中重度ARDS均无显著差异。

要点

  • 在高危钝性胸部创伤(胸部创伤严重度评分≥8)、估计PaO2/FiO2<300且无急性呼吸衰竭征象的成人中,经鼻高流量氧疗联合早期无创通气未降低气管插管率:7%(5/71)vs 8.6%(6/70),校正OR=0.72(95%CI 0.20-2.43),p=0.60。
  • 试验因无效提前终止,2年共随机141例,总体11例(7.8%)因迟发性呼吸衰竭需气管插管。
  • 肺部感染发生率实验组与对照组无显著差异:校正OR=1.99(95%CI 0.73-5.89),p=0.18。
  • 迟发性血胸无显著差异:校正OR=0.85(95%CI 0.33-2.20),p=0.74。
  • 迟发性中重度ARDS无显著差异:校正OR=2.14(95%CI 0.36-20.77),p=0.41。

适用人群与场景

  • 成人患者,高危钝性胸部创伤后48小时内收入ICU,胸部创伤严重度评分≥8,估计PaO2/FiO2<300,且无急性呼吸衰竭证据。

诊断标准与关键阈值

  • 高危钝性胸部创伤定义:胸部创伤严重度评分≥8。
  • 入组低氧血症标准:估计PaO2/FiO2<300。
  • 入组排除急性呼吸衰竭:无急性呼吸衰竭证据。
  • 对照组晚期无创通气启动指征:呼吸恶化和/或PaO2/FiO2≤200 mmHg。

处置流程与药物剂量

  • 实验策略:经鼻高流量氧疗联合早期无创通气,每例患者至少48小时。
  • 对照策略:常规氧疗联合晚期无创通气,仅在呼吸恶化和/或PaO2/FiO2≤200 mmHg时启用。

红旗征与不能漏的情况

  • 呼吸恶化或PaO2/FiO2≤200 mmHg时,对照组需启动晚期无创通气。

研究设计与关键结果

  • OptiTHO为随机、开放标签、多中心试验,历时2年,因无效提前终止,共随机141例。
  • 主要终点:因迟发性呼吸衰竭需气管插管率,实验组7%(5/71)vs 对照组8.6%(6/70),校正OR=0.72(95%CI 0.20-2.43),p=0.60。
  • 总体气管插管率:11例(7.8%)因迟发性呼吸衰竭需插管。
  • 次要终点肺部感染:实验组vs对照组校正OR=1.99(95%CI 0.73-5.89),p=0.18。
  • 次要终点迟发性血胸:实验组vs对照组校正OR=0.85(95%CI 0.33-2.20),p=0.74。
  • 次要终点迟发性中重度ARDS:实验组vs对照组校正OR=2.14(95%CI 0.36-20.77),p=0.41。

证据类型、等级与局限

  • 证据类型:随机、开放标签、多中心试验(OptiTHO)。
  • 试验因无效提前终止,共随机141例。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在高危钝性胸部创伤、非严重低氧血症且无急性呼吸衰竭征象的患者中,经鼻高流量氧疗联合预防性无创通气与常规氧疗联合晚期无创通气相比,未降低气管插管率或次要呼吸并发症(作者结论)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The benefit-risk ratio of prophylactic non-invasive ventilation (NIV) and high-flow nasal oxygen therapy (HFNC-O2) during the early stage of blunt chest trauma remains controversial because of limited data. The main objective of this study was to compare the rate of endotracheal intubation between two NIV strategies in high-risk blunt chest trauma patients.

METHODS: The OptiTHO trial was a randomized, open-label, multicenter trial over a two-year period. Every adult patients admitted in intensive care unit within 48 h after a high-risk blunt chest trauma (Thoracic Trauma Severity Score ≥ 8), an estimated PaO2/FiO2 ratio < 300 and no evidence of acute respiratory failure were eligible for study enrollment (Clinical Trial Registration: NCT03943914). The primary objective was to compare the rate of endotracheal intubation for delayed respiratory failure between two NIV strategies: i) a prompt association of HFNC-O2 and "early" NIV in every patient for at least 48 h with vs. ii) the standard of care associating COT and "late" NIV, indicated in patients with respiratory deterioration and/or PaO2/FiO2 ratio ≤ 200 mmHg. Secondary outcomes were the occurrence of chest trauma-related complications (pulmonary infection, delayed hemothorax or moderate-to-severe ARDS).

RESULTS: Study enrollment was stopped for futility after a 2-year study period and randomization of 141 patients. Overall, 11 patients (7.8%) required endotracheal intubation for delayed respiratory failure. The rate of endotracheal intubation was not significantly lower in patients treated with the experimental strategy (7% [5/71]) when compared to the control group (8.6% [6/70]), with an adjusted OR = 0.72 (95%IC: 0.20-2.43), p = 0.60. The occurrence of pulmonary infection, delayed hemothorax or delayed ARDS was not significantly lower in patients treated by the experimental strategy (adjusted OR = 1.99 [95%IC: 0.73-5.89], p = 0.18, 0.85 [95%IC: 0.33-2.20], p = 0.74 and 2.14 [95%IC: 0.36-20.77], p = 0.41, respectively).

CONCLUSION: A prompt association of HFNC-O2 with preventive NIV did not reduce the rate of endotracheal intubation or secondary respiratory complications when compared to COT and late NIV in high-risk blunt chest trauma patients with non-severe hypoxemia and no sign of acute respiratory failure.

CLINICAL TRIAL REGISTRATION: NCT03943914, Registered 7 May 2019.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Carrié C, Rieu B, Benard A, et al. Early non-invasive ventilation and high-flow nasal oxygen therapy for preventing endotracheal intubation in hypoxemic blunt chest trauma patients: the OptiTHO randomized trial. Crit Care. 2023. PMID: 37101272. doi:10.1186/s13054-023-04429-2

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。